Finerenone Clinical Trials

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

Total Trials

Recruiting

Completed

341,809

Total Enrollment

States

Finerenone Evidence & Publications

196 peer-reviewed publications + per-arm primary-outcome data from 3 pivotal trials.

See published evidence →

Finerenone Clinical Trials

Sortable list of all 75 Finerenone trials — recruiting status, pivotal acronyms, indication grouping, NCT links.

See all trials →

Finerenone History and Updates

Every FDA approval, label revision, recall, trial milestone, and pivotal publication for Finerenone — sourced from openFDA, ClinicalTrials.gov, and PubMed.

See full history →

Recent Finerenone updates

See full history →

Finerenone Study Results Published for Type 1 Diabetes and CKD· Jan 1, 2026
Finerenone Completes Phase 3 Trial for Non-diabetic Chronic Kidney Disease· Dec 31, 2025
Finerenone Phase 3 Trial for Type 2 Diabetes Completes Primary Study· Nov 25, 2025
Finerenone Reduces CV Death, HF Events in Heart Failure with LVEF ≥40%· Aug 26, 2025
Finerenone Phase 3 Trial for CKD and Type 1 Diabetes Completes· Aug 20, 2025
Kerendia (Finerenone) Receives FDA Supplemental Efficacy Approval· Jul 11, 2025
Finerenone Meta-Analysis on MRAs in Heart Failure Published in Lancet· Jan 1, 2024
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction…· Jan 1, 2024

What Is Finerenone?

Finerenone is an FDA-approved medication for chronic kidney disease associated with type 2 diabetes. It is a non-steroidal, selective mineralocorticoid receptor antagonist (MRA). This means finerenone works by blocking the mineralocorticoid receptor, which can help reduce inflammation and scarring in the kidneys and heart that can be caused by overactivity of this receptor.

Beyond its approved use, finerenone is being investigated in a wide range of clinical trials for several conditions. Researchers are studying its potential to treat various forms of chronic kidney disease, type 2 diabetes mellitus, and heart failure. Other areas of investigation include primary aldosteronism, diabetic kidney disease, and proteinuria. The earliest trial for finerenone began on November 17, 2011, and the latest is expected to conclude on April 28, 2026. In total, 75 clinical trials have been conducted or are ongoing for finerenone. Of these, 28 trials are currently recruiting participants, and 28 have been completed. These studies have collectively enrolled a significant number of participants, totaling 341,809 individuals.

Uses and Conditions Under Study

Finerenone is primarily studied for conditions affecting the kidneys and heart, often in the context of diabetes. The drug's mechanism as a mineralocorticoid receptor antagonist suggests it may help by reducing inflammation and scarring in these organs.

Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD): CKD is a long-term condition where the kidneys gradually lose their ability to filter waste from the blood. Diabetic kidney disease is a common complication of diabetes that can lead to kidney failure. Finerenone is being investigated for its potential to slow the progression of kidney damage, particularly in people with type 2 diabetes. A significant number of trials, totaling 35, are exploring finerenone for various forms of chronic kidney disease, diabetic kidney disease, and proteinuria.
Type 2 Diabetes Mellitus (T2DM): This condition involves high blood sugar levels due to the body not producing enough insulin or not using it effectively. While finerenone does not directly treat blood sugar, its role in managing kidney complications frequently associated with T2DM makes it a relevant area of study. There are 18 trials investigating finerenone in people with type 2 diabetes or type 2 diabetes mellitus.
Heart Failure (HF): Heart failure occurs when the heart cannot pump enough blood to meet the body's needs. Finerenone, as an MRA, may help reduce the strain on the heart and improve outcomes, especially in patients with heart failure with preserved ejection fraction (LVEF ≥ 40%). Studies include both adult and pediatric populations, with a total of 13 trials focusing on heart failure.
Primary Aldosteronism: This condition is characterized by the adrenal glands producing too much aldosterone, which can lead to high blood pressure. As finerenone is a mineralocorticoid receptor antagonist, it directly targets the overactivity of aldosterone. There are 5 trials studying finerenone for primary aldosteronism.

Dosing

Finerenone has been studied in several dosage forms and strengths, primarily administered orally once daily. The specific dose often depends on the condition being treated and individual patient factors like kidney function and potassium levels.

For adult use, finerenone is commonly studied as an oral tablet. Strengths investigated include 10 mg and 20 mg, with some trials exploring a range of 10 mg to 40 mg daily. Other tablet strengths studied include 1.25 mg, 2.5 mg, 5 mg, 7.5 mg, and 15 mg. The dosage may be adjusted based on a patient's estimated glomerular filtration rate (eGFR) and serum potassium levels, and treatment may be interrupted or discontinued if safety criteria are met, especially in cases of hyperkalemia (high potassium levels).

Finerenone has also been studied in pediatric formulations. These include an oral suspension and orally disintegrating tablets (ODT), with strengths such as 0.25 mg and 1.25 mg. Additionally, oral solution forms have been investigated in strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg. Treatment duration in some trials has been approximately 270 days.

Side Effects

The most common side effect reported in clinical trials for Finerenone was hyperkalaemia (high potassium levels). In studies involving over 9,500 patients, 10.5% of patients taking Finerenone experienced hyperkalaemia, compared to 5.0% on placebo.

Other common side effects observed in patients taking Finerenone included:

Nasopharyngitis (common cold symptoms): 8.3% of patients on Finerenone compared to 8.8% on placebo.
Arthralgia (joint pain): 6.7% of patients on Finerenone compared to 6.2% on placebo.
Back pain: 6.7% of patients on Finerenone compared to 6.5% on placebo.
Anemia: 6.1% of patients on Finerenone compared to 5.7% on placebo.
Diarrhea: 5.9% of patients on Finerenone compared to 5.6% on placebo.
Decreased glomerular filtration rate (a measure of kidney function): 5.7% of patients on Finerenone compared to 4.1% on placebo.

Some side effects were reported less frequently in patients taking Finerenone compared to placebo, such as peripheral edema (swelling in limbs), which occurred in 5.8% of patients on Finerenone versus 9.0% on placebo, and hypertension (high blood pressure) in 5.3% of patients on Finerenone versus 7.8% on placebo.

Clinical Trial Results

Heart Failure

In a Phase 2b study (NCT01807221) involving patients with worsening chronic heart failure, type 2 diabetes, or chronic kidney disease, Finerenone was compared to Eplerenone (INSPRA). At the 10-20 mg once-daily dose, 38.8% of participants taking Finerenone experienced a greater than 30% reduction in NT-proBNP (a marker for heart failure severity) from baseline to day 90, compared to 37.2% of participants taking Eplerenone. Finerenone generally led to reductions in both diastolic and systolic blood pressure, similar to Eplerenone. However, Finerenone also increased serum potassium levels by up to 0.275 millimoles per liter (mmol/L), similar to Eplerenone.

Another study (NCT04435626) evaluated Finerenone in patients with heart failure and preserved ejection fraction (HFpEF). Finerenone reduced the occurrence of cardiovascular death and total heart failure events; 624 participants on Finerenone experienced these events (totaling 1083 events), compared to 719 participants on placebo (totaling 1283 events). Similarly, for total heart failure events alone, 479 participants on Finerenone experienced events (totaling 842 events), versus 573 participants on placebo (totaling 1024 events). Patients taking Finerenone also reported a greater improvement in heart failure symptoms, with an average increase of 7.99 points on the Kansas City Cardiomyopathy Questionnaire (KCCQ) symptom score, compared to 6.43 points for those on placebo. However, more participants on Finerenone experienced renal composite events (75 participants) compared to placebo (55 participants).

Diabetic Kidney Disease

In a study (NCT01874431) of patients with type 2 diabetes and diabetic nephropathy, Finerenone significantly reduced the urinary albumin-to-creatinine ratio (UACR), a marker of kidney damage. At the 20 mg dose, Finerenone reduced UACR by a ratio of 0.585 from baseline to day 90, meaning a substantial reduction, compared to a ratio of 0.938 for placebo. However, Finerenone led to a greater average decrease in estimated glomerular filtration rate (eGFR), ranging from 2.364 to 4.192 mL/min/1.73m^2, compared to a decrease of 1.578 mL/min/1.73m^2 for placebo. Serum potassium levels also increased with Finerenone by up to 0.238 mmol/L, while placebo showed a minimal increase of 0.002 mmol/L.

Two large studies (NCT02540993 and NCT02545049) further investigated Finerenone in patients with type 2 diabetes and diabetic kidney disease. In NCT02540993, 367 participants on Finerenone experienced a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure, compared to 420 participants on placebo. For severe kidney-related events (onset of kidney failure, a sustained decrease in eGFR of ≥57%, or renal death), 252 participants on Finerenone were affected, versus 326 participants on placebo. UACR was reduced by a ratio of 0.655 with Finerenone compared to 0.952 with placebo.

Similarly, in NCT02545049, 458 participants on Finerenone experienced the cardiovascular composite endpoint, compared to 519 participants on placebo. For severe kidney-related events (onset of kidney failure, a sustained decrease in eGFR of ≥57%, or renal death), 108 participants on Finerenone were affected, versus 139 participants on placebo. UACR was reduced by a ratio of 0.624 with Finerenone compared to 0.922 with placebo.

Currently Recruiting Trials

Researchers are actively seeking participants for numerous clinical trials investigating finerenone across a range of conditions. These studies aim to understand how finerenone can improve outcomes for patients with various heart and kidney diseases. One Phase 4 study, NCT07442448, sponsored by Cathay General Hospital, is evaluating the impact of finerenone on myocardial remodeling in 40 patients with diabetic kidney disease and heart failure with a left ventricular ejection fraction of 40% or more. Another Phase 3 trial, NCT07181135, from the University Medical Center Groningen, is assessing the efficacy and safety of finerenone compared to placebo in reducing albuminuria in 180 participants with chronic kidney disease who are not currently using renin-angiotensin-system inhibitors. Juntendo University is sponsoring FACILITATE-HF, a Phase 4 trial (NCT07397650) enrolling 550 patients with acute heart failure and a left ventricular ejection fraction of 40% or more. This study investigates whether starting finerenone early during hospitalization offers beneficial effects. For pediatric patients, Bayer is sponsoring a Phase 3 study (NCT07188805) to learn more about finerenone's effectiveness, safety, and pharmacokinetics in 111 children with heart failure and left ventricular systolic dysfunction. The Colorado Prevention Center is leading two large Phase 3 trials. Study NCT06033950 plans to enroll 2600 patients with heart failure and reduced ejection fraction who are intolerant or ineligible for steroidal mineralocorticoid receptor antagonists. Additionally, study NCT06008197 aims for 5200 participants hospitalized with acute decompensated heart failure and mildly reduced or preserved left ventricular ejection fraction to determine finerenone's efficacy and safety on morbidity and mortality. Bayer also has a large observational study, NCT06278207, called FINEROD, which seeks to collect real-world data from 50,000 people in Asia and the United States with chronic kidney disease and type 2 diabetes who are already receiving finerenone as part of their routine care.

Where to Participate

Clinical trials for finerenone are being conducted globally, with study sites spanning 38 states, 92 cities, and 135 locations. The top cities with multiple recruiting sites include Kansas City, Missouri; Atlanta, Georgia; Boston, Massachusetts; Cincinnati, Ohio; and Philadelphia, Pennsylvania. Other cities with several sites include Indianapolis, Indiana; Baltimore, Maryland; Los Angeles, California; Hollywood, Florida; and Cleveland, Ohio. Eligibility for these studies is broad, welcoming participants of all genders. The age range for participation is from 1 to 90 years, and some studies are specifically designed for children. Healthy volunteers are also eligible for certain trials, contributing to a comprehensive understanding of finerenone.

Development Timeline

The journey of finerenone began with its first clinical trial on November 17, 2011, marking the start of a comprehensive development program. Initially, research focused on conditions such as irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia. Over time, the development pipeline significantly expanded, driven primarily by Bayer, which has sponsored 34 of the 75 total trials. Finerenone's research broadened to encompass a wide array of cardiovascular and renal conditions. Key areas of investigation now include various forms of heart failure, primary aldosteronism, diabetic kidney disease, and chronic kidney diseases, including those with proteinuria. The drug's development has progressed through all phases, with 22 Phase 4 studies, 19 Phase 3 studies, and 9 Phase 2 studies contributing to its understanding. The latest trial is projected to conclude on April 28, 2026, reflecting ongoing commitment to exploring finerenone's potential. The total enrollment across all trials has reached an impressive 341,809 participants, demonstrating a substantial effort to gather extensive data on its safety and efficacy.

Finerenone Development Timeline

Clinical trial activity from 1995 to 2026.

2026

NCT07192952PHASE3recruiting

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

117 enrolled

NCT07537088PHASE4not yet recruiting

Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease

468 enrolled

NCT07554469not yet recruiting

An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score

500 enrolled

NCT07523867PHASE4not yet recruiting

Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study

60 enrolled

NCT07442448PHASE4enrolling by invitation

Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure

40 enrolled

NCT07547878PHASE4not yet recruiting

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

64 enrolled

NCT07181135PHASE3enrolling by invitation

FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors

180 enrolled

NCT07397650PHASE4recruiting

Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure

550 enrolled

NCT07351864PHASE4not yet recruiting

Finerenone Plus SGLT2 Inhibitors in Heart Failure

60 enrolled

NCT07326631NAnot yet recruiting

Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure

120 enrolled

2025

NCT07270367PHASE3not yet recruiting

Finerenone and Cardiac Remodeling

156 enrolled

NCT07379840recruiting

A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea

300 enrolled

NCT07223502PHASE3recruiting

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

30 enrolled

NCT06954090PHASE4enrolling by invitation

Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

50 enrolled

NCT07235891PHASE4not yet recruiting

Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease

40 enrolled

NCT07232537recruiting

An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea

500 enrolled

NCT07188805PHASE3recruiting

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

111 enrolled

NCT07155694PHASE4not yet recruiting

Role of Finerenone in African American Veterans With Diabetic Kidney Disease

30 enrolled

NCT06763146active not recruiting

An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice

1,200 enrolled

NCT07124039completed

An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.

6,537 enrolled

NCT07239570PHASE4recruiting

A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease

125 enrolled

NCT07315191PHASE4recruiting

Finerenone Therapy for Pediatric HSPN With Mild Proteinuria

116 enrolled

NCT07056595NArecruiting

Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial

30 enrolled

NCT06906081PHASE2recruiting

Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

100 enrolled

NCT06835322PHASE2completed

Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis

100 enrolled

NCT06818305PHASE2terminated

Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT

10 enrolled

2024

NCT06727409PHASE4recruiting

Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease

82 enrolled

NCT07026539PHASE4recruiting

Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.

80 enrolled

NCT06608212active not recruiting

An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States

150,000 enrolled

NCT06580288PHASE3not yet recruiting

Effect of Finerenone in IgA Nephropathy

120 enrolled

NCT06573411PHASE4recruiting

Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy

116 enrolled

NCT06058585PHASE3recruiting

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

1,000 enrolled

NCT06033950PHASE3recruiting

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists

2,600 enrolled

NCT06094920PHASE4completed

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

12 enrolled

NCT06024746PHASE3recruiting

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)

1,500 enrolled

NCT06082063PHASE3recruiting

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

2,000 enrolled

NCT06457074PHASE4recruiting

Finerenone for Patients With Primary Aldosteronism (FAIRY)

306 enrolled

NCT06278207recruiting

An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

50,000 enrolled

NCT06059664PHASE2recruiting

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

100 enrolled

NCT06381323PHASE4completed

The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism

55 enrolled

NCT05901831PHASE3completed

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

241 enrolled

NCT06244758PHASE3completed

Finerenone and Renal Oxidative Stress

91 enrolled

NCT06008197PHASE3recruiting

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

5,200 enrolled

2023

NCT06164379PHASE4unknown

Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism

150 enrolled

NCT06838416recruiting

Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease

300 enrolled

NCT05887817PHASE4active not recruiting

Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)

100 enrolled

NCT05552339completed

A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients

348 enrolled

NCT05897372PHASE2terminated

Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study

1 enrolled

NCT05924620PHASE4completed

Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism

60 enrolled

NCT05703880completed

An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

15,948 enrolled

NCT05814770PHASE4unknown

Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism

96 enrolled

NCT07116512PHASE1completed

A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants

60 enrolled

NCT05705271PHASE4completed

A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus

200 enrolled

2022

NCT06460987completed

Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy

245 enrolled

NCT05640180completed

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

17,847 enrolled

NCT05457283PHASE3recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

100 enrolled

NCT05526157completed

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

50,000 enrolled

NCT05254002PHASE2completed

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

1,664 enrolled

NCT05348733active not recruiting

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

4,613 enrolled

NCT05196035PHASE3recruiting

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

219 enrolled

2021

NCT05047263PHASE3completed

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

1,584 enrolled

NCT05013008PHASE2completed

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

951 enrolled

NCT04795726NAcompleted

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)

70 enrolled

2020

NCT04435626PHASE3completed

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

6,016 enrolled

NCT04477707completed

206 enrolled

2016

NCT02957396PHASE1completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects

16 enrolled

NCT02956109PHASE1completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers

16 enrolled

2015

NCT02545049PHASE3completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

7,352 enrolled

NCT02540993PHASE3completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

5,734 enrolled

2014

NCT04881994PHASE1completed

A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

27 enrolled

2013

NCT01807221PHASE2completed

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

1,066 enrolled

NCT01874431PHASE2completed

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

823 enrolled

2010

NCT04908436PHASE1completed

A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

33 enrolled

NCT01473108PHASE1completed

Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862

67 enrolled

1995

NCT02378805recruiting

Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome

800 enrolled

Conditions Under Study

Condition	NCT ID	Title	Status	Phase	Enrollment
Chronic Kidney Disease	NCT07554469	An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score	not yet recruiting	N/A	500
	NCT07547878	Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)	not yet recruiting	PHASE4	64
	NCT07181135	FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors	enrolling by invitation	PHASE3	180
	NCT07235891	Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease	not yet recruiting	PHASE4	40
	NCT07232537	An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea	recruiting	N/A	500
	NCT06763146	An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice	active not recruiting	N/A	1,200
	NCT07124039	An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.	completed	N/A	6,537
	NCT06608212	An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States	active not recruiting	N/A	150,000
	NCT06278207	An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions	recruiting	N/A	50,000
	NCT05901831	A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes	completed	PHASE3	241
	NCT06838416	Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease	recruiting	N/A	300
	NCT05552339	A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients	completed	N/A	348
	NCT05703880	An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions	completed	N/A	15,948
	NCT05705271	A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus	completed	PHASE4	200
	NCT05640180	An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results	completed	N/A	17,847
	NCT05457283	A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria	recruiting	PHASE3	100
	NCT05526157	An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice	completed	N/A	50,000
	NCT05254002	A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes	completed	PHASE2	1,664
	NCT05348733	A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting	active not recruiting	N/A	4,613
	NCT05196035	A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria	recruiting	PHASE3	219
	NCT05013008	An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants	completed	PHASE2	951
	NCT02540993	Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease	completed	PHASE3	5,734
	NCT04908436	A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution	completed	PHASE1	33
Type 2 Diabetes Mellitus	NCT07554469	An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score	not yet recruiting	N/A	500
	NCT07232537	An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea	recruiting	N/A	500
	NCT06763146	An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice	active not recruiting	N/A	1,200
	NCT07124039	An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.	completed	N/A	6,537
	NCT06608212	An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States	active not recruiting	N/A	150,000
	NCT06278207	An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions	recruiting	N/A	50,000
	NCT06838416	Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease	recruiting	N/A	300
	NCT05552339	A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients	completed	N/A	348
	NCT05703880	An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions	completed	N/A	15,948
	NCT05705271	A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus	completed	PHASE4	200
	NCT05526157	An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice	completed	N/A	50,000
	NCT05254002	A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes	completed	PHASE2	1,664
	NCT05348733	A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting	active not recruiting	N/A	4,613
	NCT05013008	An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants	completed	PHASE2	951
Heart Failure	NCT07523867	Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study	not yet recruiting	PHASE4	60
	NCT07442448	Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure	enrolling by invitation	PHASE4	40
	NCT07351864	Finerenone Plus SGLT2 Inhibitors in Heart Failure	not yet recruiting	PHASE4	60
	NCT07326631	Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure	not yet recruiting	NA	120
	NCT07270367	Finerenone and Cardiac Remodeling	not yet recruiting	PHASE3	156
	NCT06033950	A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists	recruiting	PHASE3	2,600
	NCT06024746	A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)	recruiting	PHASE3	1,500
	NCT06082063	Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes	recruiting	PHASE3	2,000
	NCT06008197	A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients	recruiting	PHASE3	5,200
	NCT04435626	Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%	completed	PHASE3	6,016
	NCT01807221	Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone	completed	PHASE2	1,066
Primary Aldosteronism	NCT06457074	Finerenone for Patients With Primary Aldosteronism (FAIRY)	recruiting	PHASE4	306
	NCT06381323	The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism	completed	PHASE4	55
	NCT06164379	Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism	unknown	PHASE4	150
	NCT05924620	Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism	completed	PHASE4	60
	NCT05814770	Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism	unknown	PHASE4	96
Diabetic Kidney Disease	NCT07523867	Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study	not yet recruiting	PHASE4	60
	NCT07155694	Role of Finerenone in African American Veterans With Diabetic Kidney Disease	not yet recruiting	PHASE4	30
	NCT05897372	Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study	terminated	PHASE2	1
	NCT02545049	Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease	completed	PHASE3	7,352
Type 2 Diabetes	NCT07547878	Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)	not yet recruiting	PHASE4	64
	NCT06906081	Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study	recruiting	PHASE2	100
	NCT05887817	Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)	active not recruiting	PHASE4	100
	NCT05640180	An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results	completed	N/A	17,847
Chronic Kidney Diseases	NCT06058585	The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect	recruiting	PHASE3	1,000
	NCT06094920	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	completed	PHASE4	12
	NCT05887817	Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)	active not recruiting	PHASE4	100
Proteinuria	NCT06460987	Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy	completed	N/A	245
	NCT05457283	A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria	recruiting	PHASE3	100
	NCT05196035	A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria	recruiting	PHASE3	219
Heart Failure (Pediatric)	NCT07192952	A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction	recruiting	PHASE3	117
	NCT07188805	A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction	recruiting	PHASE3	111
Chronic Kidney Disease(CKD)	NCT07239570	A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease	recruiting	PHASE4	125
	NCT06818305	Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT	terminated	PHASE2	10
Chronic Kidney Disease Due to Type 2 Diabetes Mellitus	NCT07026539	Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.	recruiting	PHASE4	80
	NCT06094920	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	completed	PHASE4	12
Pharmacokinetics	NCT02957396	Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects	completed	PHASE1	16
	NCT02956109	Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers	completed	PHASE1	16
Worsening Chronic Heart Failure	NCT04881994	A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution	completed	PHASE1	27
	NCT04908436	A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution	completed	PHASE1	33
Diabetic Retinopathy	NCT04795726	A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)	completed	NA	70
	NCT04477707	A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)	completed	N/A	206
Albuminuria	NCT06954090	Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study	enrolling by invitation	PHASE4	50
	NCT06094920	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	completed	PHASE4	12
Finerenone	NCT06381323	The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism	completed	PHASE4	55
	NCT06460987	Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy	completed	N/A	245
Cardiovascular Diseases	NCT07026539	Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.	recruiting	PHASE4	80
	NCT06082063	Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes	recruiting	PHASE3	2,000
IgA Nephropathy	NCT06580288	Effect of Finerenone in IgA Nephropathy	not yet recruiting	PHASE3	120
	NCT06460987	Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy	completed	N/A	245
Acute Heart Failure	NCT07397650	Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure	recruiting	PHASE4	550
	NCT06008197	A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients	recruiting	PHASE3	5,200
Left Ventricular Systolic Dysfunction	NCT07192952	A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction	recruiting	PHASE3	117
	NCT07188805	A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction	recruiting	PHASE3	111
Diabetic Neuropathies	NCT06906081	Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study	recruiting	PHASE2	100
Familial Benign Hematuria	NCT02378805	Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome	recruiting	N/A	800
Glomerulonephritis	NCT06835322	Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis	completed	PHASE2	100
Healthy Volunteers	NCT07116512	A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants	completed	PHASE1	60
Heart Failure and Mildly Reduced Ejection Fraction	NCT07442448	Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure	enrolling by invitation	PHASE4	40
Heart Failure and Preserved Ejection Fraction	NCT07442448	Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure	enrolling by invitation	PHASE4	40
Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent	NCT07116512	A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants	completed	PHASE1	60
Henoch Schönlein Purpura Nephritis	NCT07315191	Finerenone Therapy for Pediatric HSPN With Mild Proteinuria	recruiting	PHASE4	116
Hereditary Kidney Disease	NCT02378805	Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome	recruiting	N/A	800
Hyperkalemia	NCT07523867	Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study	not yet recruiting	PHASE4	60
Hypertension	NCT05814770	Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism	unknown	PHASE4	96
Hypertension (HTN)	NCT07223502	A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease	recruiting	PHASE3	30
IgA Nephropathy (IgAN)	NCT07056595	Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial	recruiting	NA	30
Kidney Transplant; Complications	NCT06059664	The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study	recruiting	PHASE2	100
Mineralocorticoid Receptor Antagonist	NCT06381323	The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism	completed	PHASE4	55
Nephrectomy	NCT06818305	Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT	terminated	PHASE2	10
Non-diabetic Chronic Kidney Disease	NCT05047263	A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease	completed	PHASE3	1,584
Patients With Type 2 Diabetes	NCT06727409	Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease	recruiting	PHASE4	82
Pediatric Kidney Disease	NCT02378805	Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome	recruiting	N/A	800
Primary Membranous Nephropathy	NCT06573411	Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy	recruiting	PHASE4	116
Renal Cell Carcinoma (Kidney Cancer)	NCT06818305	Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT	terminated	PHASE2	10
Renal Cell Carcinoma (RCC)	NCT06818305	Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT	terminated	PHASE2	10
Renal Function	NCT06838416	Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease	recruiting	N/A	300
Retinal Nerve Fiber Layer Thickness	NCT07235891	Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease	not yet recruiting	PHASE4	40
Safety Issues	NCT06460987	Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy	completed	N/A	245
T2DM (Type 2 Diabetes Mellitus)	NCT07537088	Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease	not yet recruiting	PHASE4	468
Thin Basement Membrane Disease	NCT02378805	Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome	recruiting	N/A	800
Type 1 Diabetes	NCT06082063	Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes	recruiting	PHASE3	2,000
Type 1 Diabetes Mellitus	NCT05901831	A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes	completed	PHASE3	241
Type 2 Diabetes Mellitus (T2DM)	NCT07026539	Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.	recruiting	PHASE4	80
Type 2 DM	NCT06954090	Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study	enrolling by invitation	PHASE4	50
Type 2 DM /Diabetic Nephropathy	NCT06954090	Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study	enrolling by invitation	PHASE4	50
Type2diabetes	NCT06244758	Finerenone and Renal Oxidative Stress	completed	PHASE3	91
Kidney Failure	NCT06082063	Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes	recruiting	PHASE3	2,000
Alport Syndrome	NCT02378805	Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome	recruiting	N/A	800
Cardiovascular Autonomic Neuropathy	NCT06906081	Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study	recruiting	PHASE2	100
Children	NCT05457283	A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria	recruiting	PHASE3	100
Chronic Heart Failure	NCT07379840	A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea	recruiting	N/A	300
Chronic Kidney Disease stage3	NCT06094920	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	completed	PHASE4	12
Chronic Kidney Disease stage4	NCT06094920	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	completed	PHASE4	12
CKD	NCT06094920	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	completed	PHASE4	12
CKD - Chronic Kidney Disease	NCT07537088	Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease	not yet recruiting	PHASE4	468
CKD Stage 3	NCT06094920	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	completed	PHASE4	12
CKD Stage 4	NCT06094920	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	completed	PHASE4	12
Clinical Pharmacology	NCT01473108	Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862	completed	PHASE1	67
Diabetes	NCT06094920	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	completed	PHASE4	12
Diabetes Complications	NCT06094920	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	completed	PHASE4	12
Diabetes Mellitus	NCT06094920	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	completed	PHASE4	12
Diabetes Mellitus Type 2 With Proteinuria	NCT06094920	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	completed	PHASE4	12
Diabetes Mellitus, Type 2	NCT06094920	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	completed	PHASE4	12
Diabetic Kidney Disease (DKD)	NCT07326631	Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure	not yet recruiting	NA	120
Diabetic Nephropathies	NCT01874431	Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy	completed	PHASE2	823
Diabetic Nephropathy	NCT04881994	A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution	completed	PHASE1	27

All Finerenone Clinical Trials (75)

NCT ID	Title	Status	Phase	Enrollment	Sponsor
NCT07192952	A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction	recruiting	PHASE3	117	Bayer
NCT07537088	Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease	not yet recruiting	PHASE4	468	First Affiliated Hospital of Wannan Medical College
NCT07554469	An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score	not yet recruiting	N/A	500	Bayer
NCT07523867	Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study	not yet recruiting	PHASE4	60	Hospital de Messejana Dr. Carlos Alberto Studart Gomes
NCT07442448	Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure	enrolling by invitation	PHASE4	40	Cathay General Hospital
NCT07547878	Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)	not yet recruiting	PHASE4	64	Baylor Research Institute
NCT07181135	FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors	enrolling by invitation	PHASE3	180	University Medical Center Groningen
NCT07397650	Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure	recruiting	PHASE4	550	Juntendo University
NCT07351864	Finerenone Plus SGLT2 Inhibitors in Heart Failure	not yet recruiting	PHASE4	60	Mansoura University
NCT07326631	Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure	not yet recruiting	NA	120	College of Physicians and Surgeons Pakistan
NCT07270367	Finerenone and Cardiac Remodeling	not yet recruiting	PHASE3	156	Subodh Verma
NCT07379840	A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea	recruiting	N/A	300	Bayer
NCT07223502	A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease	recruiting	PHASE3	30	Sarfez Pharmaceuticals, Inc.
NCT06954090	Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study	enrolling by invitation	PHASE4	50	Steno Diabetes Center Copenhagen
NCT07235891	Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease	not yet recruiting	PHASE4	40	Alexandria University
NCT07232537	An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea	recruiting	N/A	500	Bayer
NCT07188805	A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction	recruiting	PHASE3	111	Bayer
NCT07155694	Role of Finerenone in African American Veterans With Diabetic Kidney Disease	not yet recruiting	PHASE4	30	Washington D.C. Veterans Affairs Medical Center
NCT06763146	An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice	active not recruiting	N/A	1,200	Bayer
NCT07124039	An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.	completed	N/A	6,537	Bayer
NCT07239570	A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease	recruiting	PHASE4	125	Peter Rossing
NCT07315191	Finerenone Therapy for Pediatric HSPN With Mild Proteinuria	recruiting	PHASE4	116	Capital Institute of Pediatrics, China
NCT07056595	Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial	recruiting	NA	30	Botkin Hospital
NCT06906081	Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study	recruiting	PHASE2	100	Peter Rossing
NCT06835322	Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis	completed	PHASE2	100	Alexandria University
NCT06818305	Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT	terminated	PHASE2	10	Jinling Hospital, China
NCT06727409	Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease	recruiting	PHASE4	82	Chinese University of Hong Kong
NCT07026539	Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.	recruiting	PHASE4	80	University of Aarhus
NCT06608212	An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States	active not recruiting	N/A	150,000	Bayer
NCT06580288	Effect of Finerenone in IgA Nephropathy	not yet recruiting	PHASE3	120	Zhejiang University
NCT06573411	Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy	recruiting	PHASE4	116	First Affiliated Hospital, Sun Yat-Sen University
NCT06058585	The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect	recruiting	PHASE3	1,000	The George Institute
NCT06033950	A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists	recruiting	PHASE3	2,600	Colorado Prevention Center
NCT06094920	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	completed	PHASE4	12	University Medical Center Groningen
NCT06024746	A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)	recruiting	PHASE3	1,500	Colorado Prevention Center
NCT06082063	Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes	recruiting	PHASE3	2,000	Steno Diabetes Center Copenhagen
NCT06457074	Finerenone for Patients With Primary Aldosteronism (FAIRY)	recruiting	PHASE4	306	Qifu Li
NCT06278207	An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions	recruiting	N/A	50,000	Bayer
NCT06059664	The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study	recruiting	PHASE2	100	University of North Carolina, Chapel Hill
NCT06381323	The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism	completed	PHASE4	55	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT05901831	A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes	completed	PHASE3	241	Bayer
NCT06244758	Finerenone and Renal Oxidative Stress	completed	PHASE3	91	University of Erlangen-Nürnberg Medical School
NCT06008197	A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients	recruiting	PHASE3	5,200	Colorado Prevention Center
NCT06164379	Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism	unknown	PHASE4	150	Shanghai Jiao Tong University School of Medicine
NCT06838416	Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease	recruiting	N/A	300	Second Affiliated Hospital of Soochow University
NCT05887817	Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)	active not recruiting	PHASE4	100	Saga University
NCT05552339	A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients	completed	N/A	348	Bayer
NCT05897372	Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study	terminated	PHASE2	1	Iain Bressendorff
NCT05924620	Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism	completed	PHASE4	60	Chongqing Medical University
NCT05703880	An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions	completed	N/A	15,948	Bayer
NCT05814770	Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism	unknown	PHASE4	96	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT07116512	A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants	completed	PHASE1	60	Bayer
NCT05705271	A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus	completed	PHASE4	200	Bayer
NCT06460987	Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy	completed	N/A	245	The Fourth Affiliated Hospital of Zhejiang University School of Medicine
NCT05640180	An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results	completed	N/A	17,847	Bayer
NCT05457283	A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria	recruiting	PHASE3	100	Bayer
NCT05526157	An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice	completed	N/A	50,000	Bayer
NCT05254002	A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes	completed	PHASE2	1,664	Bayer
NCT05348733	A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting	active not recruiting	N/A	4,613	Bayer
NCT05196035	A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria	recruiting	PHASE3	219	Bayer
NCT05047263	A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease	completed	PHASE3	1,584	Bayer
NCT05013008	An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants	completed	PHASE2	951	Bayer
NCT04795726	A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)	completed	NA	70	Bayer
NCT04435626	Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%	completed	PHASE3	6,016	Bayer
NCT04477707	A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)	completed	N/A	206	Bayer
NCT02957396	Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects	completed	PHASE1	16	Bayer
NCT02956109	Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers	completed	PHASE1	16	Bayer
NCT02545049	Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease	completed	PHASE3	7,352	Bayer
NCT02540993	Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease	completed	PHASE3	5,734	Bayer
NCT04881994	A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution	completed	PHASE1	27	Bayer
NCT01807221	Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone	completed	PHASE2	1,066	Bayer
NCT01874431	Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy	completed	PHASE2	823	Bayer
NCT04908436	A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution	completed	PHASE1	33	Bayer
NCT01473108	Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862	completed	PHASE1	67	Bayer
NCT02378805	Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome	recruiting	N/A	800	University Hospital Goettingen

Where to Participate: All Finerenone Trial Sites in the U.S. (102 sites across 33 states)

Every actively recruiting Finerenonetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Birmingham, AL Investigative Site 10012	Birmingham35205	NCT06008197	Map
AL	CON-10004 Fairhope, AL Investigational Site	Fairhope36532	NCT06024746	Map
AL	Fairhope, AL Investigative Site 10004	Fairhope36532	NCT06008197	Map
AL	FIN-10004 Fairhope, AL Investigational Site	Fairhope36532	NCT06033950	Map
AL	Huntsville, AL Investigative Site 10026	Huntsville35801	NCT06008197	Map
AZ	Glendale, AZ Investigative Site 10096	Glendale85304	NCT06008197	Map
AZ	Scottsdale, AZ Investigative Site 10003	Scottsdale85258	NCT06008197	Map
CA	Chula Vista, CA Investigative Site 10111	Chula Vista91911	NCT06008197	Map
CA	CON-10075 El Centro, CA Investigational Site	El Centro92243	NCT06024746	Map
CA	Huntington Beach, CA Investigative Site 10031	Huntington Beach92648	NCT06008197	Map
CA	Los Angeles, CA Investigative Site 10089	Los Angeles90073	NCT06008197	Map
CA	Lucille Packard Children's Hospital Stanford - Pediatric Nephrology	Palo Alto94304	NCT05457283	Map
CA	Lucille Packard Children's Hospital Stanford - Pediatric Nephrology	Palo Alto94304	NCT05196035	Map
CA	CON-10024 Sacramento, CA Investigational Site	Sacramento95816	NCT06024746	Map
CA	Sacramento, CA Investigative Site 10024	Sacramento95816	NCT06008197	Map
CA	FIN-10075 San Diego, CA Investigational Site	San Diego92243	NCT06033950	Map
CA	UC San Diego - Altman Clinical and Translational Research Institute (ACTRI) - Linda Vista Clinic	San Diego92023	NCT05196035	Map
CA	San Francisco, CA Investigative Site 10023	San Francisco94118	NCT06008197	Map
CA	Tarzana, CA Investigative Site 10409	Tarzana91356	NCT06008197	Map
CA	Van Nuys, CA Investigative Site 10109	Van Nuys91405	NCT06008197	Map
CA	West Hills, CA Investigative Site 10013	West Hills91307	NCT06008197	Map
CO	Aurora, CO Investigative Site 10001	Aurora80045	NCT06008197	Map
CO	Denver, CO Investigative Site 10005	Denver80204	NCT06008197	Map
FL	Bradenton, FL Investigative Site 10125	Bradenton34209	NCT06008197	Map
FL	Brooksville, FL Investigative Site 10077	Brooksville34613	NCT06008197	Map
FL	Fort Lauderdale, FL Investigative Site 10114	Fort Lauderdale33308	NCT06008197	Map
FL	Fort Myers, FL Investigative Site 10076	Fort Myers33919	NCT06008197	Map
FL	Hialeah, FL Investigative Site 10104	Hialeah33012	NCT06008197	Map
FL	Memorial Transplant Institute - Pediatric Nephrology	Hollywood33021	NCT05196035	Map
FL	Jacksonville, FL Investigative Site 10028	Jacksonville32209	NCT06008197	Map
FL	Miami, FL Investigative Site 10040	Miami33173	NCT06008197	Map
FL	Miami, FL Investigative Site 10105	Miami33135	NCT06008197	Map
GA	Atlanta, GA Investigative Site 10022	Atlanta30303	NCT06008197	Map
GA	CON-10022 Atlanta, GA Investigational Site	Atlanta30303	NCT06024746	Map
GA	Duluth, GA Investigative Site 10083	Duluth30096	NCT06008197	Map
ID	Boise, Idaho Investigative Site 10073	Boise83712	NCT06008197	Map
IL	Chicago, IL Investigative Site 10062	Chicago60612	NCT06008197	Map
IL	Glenview, IL Investigative Site 10021	Glenview60026	NCT06008197	Map
IL	Naperville, IL Investigative Site 10025	Naperville60540	NCT06008197	Map
IL	Peoria, IL Investigative Site 10010	Peoria61614	NCT06008197	Map
IL	Peoria, IL Investigative Site 10019	Peoria61603	NCT06008197	Map
IN	Indianapolis, IN Investigative Site 10008	Indianapolis46260	NCT06008197	Map
IN	Indianapolis, IN Investigative Site 10074	Indianapolis46237	NCT06008197	Map
IN	Merrillville, IN Investigative Site 10064	Merrillville46410	NCT06008197	Map
KS	Kansas City, KS Investigative Site 10060	Kansas City66103	NCT06008197	Map
KY	Lexington, KY Investigative Site 10080	Lexington40503	NCT06008197	Map
KY	Lexington, KY Investigative Site 10118	Lexington40536	NCT06008197	Map
KY	Louisville, KY Investigative Site 10006	Louisville40202	NCT06008197	Map
KY	Paducah, KY Investigative Site 10079	Paducah42003	NCT06008197	Map
LA	Baton Rouge, LA Investigative Site 10030	Baton Rouge70808	NCT06008197	Map
LA	CON-10030 Baton Rouge, LA Investigational Site	Baton Rouge70808	NCT06024746	Map
LA	Hammond, LA Investigative Site 10106	Hammond70403	NCT06008197	Map
LA	West Monroe, LA Investigative Site 10090	West Monroe71291	NCT06008197	Map
MD	Baltimore, MD Investigative Site 10101	Baltimore21287	NCT06008197	Map
MD	The Charlotte R. Bloomberg Children's Center Building - Nephrology	Baltimore21287	NCT05457283	Map
MD	The Charlotte R. Bloomberg Children's Center Building - Nephrology	Baltimore21287	NCT05196035	Map
MD	Bowie, MD Investigative Site 10020	Bowie20715	NCT06008197	Map
MA	Boston, MA Investigative Stie 10087	Boston02114	NCT06008197	Map
MN	Minneapolis, MN Investigative Site 10035	Minneapolis55417	NCT06008197	Map
MN	Minneapolis, MN Investigative Site 10091	Minneapolis55407-1139	NCT06008197	Map
MO	Children's Mercy Hospital Kansas City - Nephrology	Kansas City64108	NCT05196035	Map
MO	CON-10002 Kansas City, MO Investigative Site	Kansas City64111	NCT06024746	Map
MO	FIN-10002 Kansas City, MO Investigational Site	Kansas City64111	NCT06033950	Map
MO	Kansas City, MO Investigative Site 10002	Kansas City64111	NCT06008197	Map
NE	Omaha, NE Investigative Site 10018	Omaha68105	NCT06008197	Map
NJ	Camden, NJ Investigative Site 10033	Camden08103	NCT06008197	Map
NY	Roslyn, NY Investigative Site 10058	Roslyn11576	NCT06008197	Map
NY	Stony Brook, NY Investigative Site 10017	Stony Brook11794-8171	NCT06008197	Map
NC	UNC Eastowne Kidney Transplant Clinic	Chapel Hill27514	NCT06059664	Map
OH	Akron, OH Investigative Site 10081	Akron44304	NCT06008197	Map
OH	Centerville, OH Investigative Site 10119	Centerville45459	NCT06008197	Map
OH	Cincinnati Children's Hospital Medical Center \| Division of Nephrology and Hypertension	Cincinnati45229	NCT05196035	Map
OH	Cincinnati, OH Investigative Site 10088	Cincinnati45220	NCT06008197	Map
OH	Cleveland Clinic \| Pediatric Nephrology	Cleveland14013	NCT05457283	Map
OH	Cleveland Clinic \| Pediatric Nephrology	Cleveland14013	NCT05196035	Map
OK	Bartlesville, OK Investigative Site 10095	Bartlesville74006	NCT06008197	Map
OR	OHSU Doernbecher Children's Hospital - Neurology	Portland97239	NCT05196035	Map
PA	Philadelphia, PA Investigative Site 10068	Philadelphia19107	NCT06008197	Map
PA	Pittsburg, PA Investigative Site 1044	Pittsburgh15212	NCT06008197	Map
RI	Providence, RI Investigative Site 10050	Providence02908	NCT06008197	Map
SC	Charleston, SC Investigative Site 10056	Charleston29425	NCT06008197	Map
TN	Germantown, TN Investigative Site 10063	Germantown38138	NCT06008197	Map
TN	Memphis, TN Investigative Site 10059	Memphis38105	NCT06008197	Map
TN	Nashville, TN Investigative Site 10071	Nashville37203	NCT06008197	Map
TX	Amarillo, TX Investigative Site 10045	Amarillo79106	NCT06008197	Map
TX	CON-10045 Amarillo, TX Investigational Site	Amarillo79106	NCT06024746	Map
TX	Austin, TX Investigative Site 10015	Austin78705	NCT06008197	Map
TX	CON-10015 Austin, TX Investigational Site	Austin78705	NCT06024746	Map
TX	FIN-10015 Austin, TX Investigational Site	Austin78705	NCT06033950	Map
TX	Dallas, TX Investigative Site 10042	Dallas75216	NCT06008197	Map
TX	Houston, TX Investigative Site 10085	Houston77030	NCT06008197	Map
TX	Plano, TX Investigative Site 10014	Plano75093	NCT06008197	Map
UT	Eccles Primary Children's Outpatient Services - Nephrology	Salt Lake City84113	NCT05457283	Map
UT	Eccles Primary Children's Outpatient Services - Nephrology	Salt Lake City84113	NCT05196035	Map
VT	Burlington, VT Investigative Site 10053	Burlington05401	NCT06008197	Map
VA	Norfolk, VA Investigative Site 10009	Norfolk23507	NCT06008197	Map
VA	Richmond, VA Investigative Site 10067	Richmond23249	NCT06008197	Map
VA	Richmond, VA Investigative Site 10069	Richmond23225	NCT06008197	Map
VA	Salem, VA Investigative Site 10048	Salem24153	NCT06008197	Map
VA	Sarfez Pharmaceuticals, Inc.	Vienna22182	NCT07223502	Map
WA	Seattle Children's Hospital - Nephrology	Seattle98105	NCT05196035	Map
WI	Milwaukee, WI Investigative Site 10061	Milwaukee53226	NCT06008197	Map

Browse Finerenone Trials by State

Missouri clinical trials Georgia clinical trials Massachusetts clinical trials Ohio clinical trials Pennsylvania clinical trials Indiana clinical trials Maryland clinical trials California clinical trials Florida clinical trials Utah clinical trials

finerenonechronic kidney diseasetype 2 diabetes mellitusheart failureprimary aldosteronismdiabetic kidney diseaseclinical trials

Data sourced from the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI). Report generated May 8, 2026.

Recent Finerenone updates

What Is Finerenone?

Uses and Conditions Under Study

Dosing

Side Effects

Clinical Trial Results

Currently Recruiting Trials

Where to Participate

Development Timeline

Finerenone Development Timeline

Conditions Under Study

All Finerenone Clinical Trials (75)

Sponsors

Where to Participate: All Finerenone Trial Sites in the U.S. (102 sites across 33 states)

Browse Finerenone Trials by State